All posts by admin

Business Wire India

Seoul Semiconductor Co., Ltd. (KOSDAQ: 046890), a global opto-semiconductor technology company, announced that its world’s first High Voltage (HV) opto-semiconductor technology has entered mass production with four of the world’s top automotive brands across the Americas, Europe, and Asia, with plans to expand supply to 10 models by the end of the year.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601232986/en/

 

 

 

The technology combines micro-scaled opto-semiconductor chips capable of 12V single-chip operation — as opposed to conventional 3V LEDs — with a high-voltage (HV) driver technology. This enables a reduction of more than 10% in the number of driver-related components used in hybrid and electric vehicles, while lowering power consumption by approximately 10%, contributing to cost reduction and simplification of automotive electrical systems. Seoul Semiconductor aims to leverage this global mass production rollout as a springboard to lead ‘HV Opto-Semiconductor’ as the next-generation standard technology in the hybrid and electric vehicle sectors, backed by its already-secured portfolio of hundreds of HV opto-semiconductor chip patents and more than 50 HV driver patents.

 

Seoul Semiconductor aims to leverage this global mass production rollout as a springboard to lead next-generation standard technology in the hybrid and electric vehicle sectors. The core of ‘HV Opto-Semiconductor’ technology is based on a Multi-Junction P-N structure within a single chip. Conventional 3V drive systems required voltage step-down conversion by a factor of 1/100 when applied to hybrid and electric vehicles equipped with 300V high-voltage batteries. By contrast, applying a 30V HV chip reduces the voltage conversion ratio to just 1/10, significantly cutting conversion losses.

 

 

Previously, bridging such large voltage differences required multiple conversion circuits and components, resulting in substantial power loss, heat generation, and design complexity. Seoul Semiconductor’s ‘HV Opto-Semiconductor’ technology minimizes the need for separate components, simplifying PCB design and reducing component count, while also lowering heat generation and improving durability. Compared to conventional 3V LEDs, it reduces driver costs by 20% and power consumption by 10%.

 

 

Matthew Fras, COO of North America Sales at Seoul Semiconductor, stated: “With global EV sales — including hybrids — set to surpass 20 million units this year, that number is expected to double to 40 million units in five years. As vehicles become more functionally advanced, the value of opto-semiconductors per vehicle is also projected to grow from $100 to $200, meaning the overall opto-semiconductor market will expand fourfold. We aim to significantly expand our market share through our ‘HV Opto-Semiconductor’ technology, with a goal of breaking into the global top 10 automotive brands by year-end, and we plan to elevate the automotive division to become the largest business unit within the Seoul Group this year.”

 

 

According to the International Energy Agency (IEA), 1 in 4 (25%) new vehicles sold globally in 2025 will be hybrid or electric, with that share projected to more than double to over 2 in 5 by 2030. Global demand for automotive opto-semiconductors is also forecast to grow fourfold, driven by emerging functional requirements like stylish lighting and vehicle-to-vehicle communication (TrendForce).

 

 

About Seoul Semiconductor

 

 

Seoul Semiconductor is the world’s third-largest global optoelectronics (LED) company, specializing in LED technology for over 30 years. With the vision of “Making the world clean, healthy, and beautiful through light,” it leads a new paradigm of light across various industries, including lighting, automotive, IT (such as backlighting), and its subsidiary, Seoul Viosys, which specializes in MicroLED, UV, Sensors, and Datacomm (SD).

 

 

Its groundbreaking technologies include the world’s first innovative No-wire LED technology WICOP, the SunLike LED, which replicates natural sunlight spectrum, the high-voltage LED Acrich, the ultra-bright nPola LED (10 times brighter than conventional LEDs), the RGB one-chip MicroLED WICOP Pixel, and UV sterilization technology Violeds.

 

 

Seoul Semiconductor holds an impressive portfolio of over 15,000 patents, and in the last 20 years, it has won over 100 cases in patent litigation across 8 countries. Believing that the patent system provides hope for young people and serves as a foundation for building a better world, the company is actively engaged in intellectual property protection. For more details, visit our official website (www.seoulsemicon.com or www.seoulviosys.com) and our social media channels (LinkedIn).

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260601232986/en/

 

Business Wire India

So Good India has been announced as the Title Sponsor for the Vegan India Conference 2026 (VIC 2026), one of India’s leading platforms for plant-based innovation, sustainability, and conscious consumer culture. The two-day conference will take place on June 6 -7, 2026, at the Holiday Inn Mumbai International Airport.

As Title Sponsor, So Good India will spotlight its expanding portfolio of plant-based products, including its newly launched protein range and barista-grade oat milk. Designed specifically for coffee applications, the barista range delivers on taste, texture, and frothing performance-catering to cafés, baristas, and an increasingly discerning community of coffee-conscious consumers.

With café culture and health-led consumption rapidly evolving across urban India, plant-based beverages are becoming part of everyday routines. Responding to rising demand for high-protein, functional nutrition, So Good India has expanded its portfolio across High-Protein oats, almonds, and soy-targeting label-conscious, protein-focused consumers and positioning plant-based milk as a mainstream choice. At VIC 2026, the brand will showcase this range through immersive coffee bar experiences, product displays, and high-protein smoothie sampling.

“This year’s theme, Beyond Substitutes, Toward Systems, reflects our shift from alternatives to building scalable, ethical food systems,” said Palak Mehta, Founder of the Vegan India Conference. “So Good India’s partnership mirrors the momentum of the plant-based dairy category and India’s evolving consumer mindset.”

Commenting on the partnership, Rohit Bhagat, Country Head, Life Health Foods India, which owns the brand, said: “India’s food and beverage landscape is at an inflection point, with consumers actively seeking products that align health, taste, and sustainability. Protein demand is rising rapidly as the new generation embraces more active and health-conscious lifestyles. But the real question is — how much protein is actually good enough in a drink? The ideal amount is one that delivers meaningful nutrition without compromising on taste, digestibility, or everyday convenience. As So Good caters to the entire household as a audience, we decided to go with 10g of protein per serve which is almost double the amount which is present in a glass of milk.

Vegan India Conference brings together the right ecosystem to accelerate this shift. Our association with VIC 2026 reflects our commitment to making plant-based nutrition accessible, functional, and enjoyable for everyday Indian consumers—whether at home or in cafés.”

Spanning two days, Vegan India Conference 2026 will host 65 speakers from over 10 countries and welcome 1,000+ attendees from across India. Over the years, the conference has featured distinguished Chief Guests and Special Guests such as Maneka Gandhi, former Union Minister and Member of Parliament; D. Y. Chandrachud, former Chief Justice of India; Brahmarishi Mohanji, globally renowned spiritual leader, Moby, international musician and animal rights advocate; and Kuntal Joisher, the world’s first vegan to summit Mount Everest.

Continuing this legacy, VIC 2026 will welcome Anita Dongre, globally renowned fashion designer and entrepreneur, as Guest of Honour, alongside prominent industry leaders including Rishabh Mariwala, Founder of Sharrp Ventures, and Vishnucharan Manjunath, Head of Growth and Revenue at BigBasket-underscoring the conference’s influence across policy, culture, and business.

Vegan India Conference 2026 will showcase India’s largest range of plant-based innovations, spanning artisanal cheeses, meat and dairy alternatives, proteins, desserts, and functional beverages. The conference is structured around five themes—Food, Health, Advocacy, Materials, and Innovation—spotlighting ideas shaping the future of the plant-based ecosystem.

VIC 2026 is expected to convene founders, investors, healthcare professionals, retailers, and sustainability leaders for conversations around food innovation, wellness, retail trends, and conscious living. Registrations are now open.

Business Wire India

 

News summary:

 

• Defense operations require resilient timing architectures that maintain synchronization in contested and GNSS-denied environments
• ruggedSync^™ Series OSA 5510 delivers assured timing and extended holdover in a MIL-qualified platform for tactical, deployable operations
• Zero-trust resiliency with diversified cPNT sources, including M-Code, PRS and STL, strengthens operational continuity for defense communications, navigation and mission-critical infrastructure

 

Oscilloquartz today launched its ruggedSync^™ Series OSA 5510, a ruggedized timing and synchronization platform engineered for defense and other harsh, mission-critical environments. Designed for deployment in tactical communications networks, mobile command centers (MCCs), aviation systems and other highly demanding operational environments, the OSA 5510 combines PTP grandmaster and NTP server functionality with synchronization assurance and resilient holdover in a compact MIL-qualified platform. Multi-band GNSS support, encrypted and authenticated timing options and environmental protection enable operation in contested and GNSS-denied environments where trusted synchronization must be maintained.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601763766/en/

 

 

 

“Our new ruggedSync^™ Series OSA 5510 extends the Oscilloquartz assured PNT portfolio into tactical and deployable defense environments,” said Gil Biran, GM of Oscilloquartz. “Combined with our optical cesium clocks, synchronization assurance technologies, PTP grandmasters and synchronization management solutions, it reinforces Oscilloquartz’s ability to deliver the industry’s most comprehensive timing portfolio. This enables us to support truly end-to-end, multi-layered timing architectures designed to maintain trusted synchronization and resilient PNT capabilities across highly demanding and contested environments.”

 

Built to support resilient defense timing architectures, the OSA 5510 integrates advanced synchronization technologies and flexible mission-critical interfaces within a hardened platform compliant with MIL-STD-810H and MIL-STD-461G. The solution supports IEEE 1588v2 PTP, SyncE and secure NTP services, while programmable I/O and timecode interfaces, including STANAG, Have Quick, IRIG and PPS/CLK distribution, support diverse defense payloads and operational requirements. Optical and copper SFP/SFP+ 1G/10G interfaces and dual power feeds further enable deployment across modern high-bandwidth defense networks.

 

 

The ruggedSync^™ Series OSA 5510 strengthens multi-source resilience through zero-trust architecture, with support for M-Code, Galileo PRS and Iridium STL. Extended holdover, low phase-noise outputs, and jamming and spoofing detection and mitigation help maintain continuity during GNSS degradation or disruption, while White Rabbit readiness supports advanced timing distribution use cases. The launch also builds on Oscilloquartz’s expanding global aerospace, defense and government partnerships, including regional representative and VAR relationships supporting resilient timing and assured PNT deployments across the Americas, EMEA and Asia-Pacific.

 

 

“Modern defense operations require synchronization technologies that are resilient, flexible and straightforward to integrate across diverse mission environments,” commented Igal Pinhasov, VP of product line management at Oscilloquartz. “Our OSA 5510 builds on the same core timing and synchronization technologies deployed across the broader Oscilloquartz portfolio, helping to deliver a more consistent operational experience across network layers and deployment models. By leveraging common capabilities and synchronization management approaches, organizations can simplify integration and more easily scale resilient timing infrastructures across evolving defense networks.”

 

 

About Oscilloquartz

 

 

Oscilloquartz, an Adtran company, delivers high-precision timing and synchronization solutions for mobile networks and critical infrastructure, enabling assured positioning, navigation and timing (aPNT) with multi-source resilience and long holdover. With over 75 years of expertise, Oscilloquartz combines innovation with proven reliability to strengthen network resilience in a GNSS-challenged world. Our portfolio includes optically pumped atomic cesium clocks, PTP grandmasters, GNSS receivers and advanced synchronization management tools for in-service assurance. These solutions maintain accuracy and availability even under jamming or spoofing attacks, supporting communications, power, aviation, transport, defense, finance and broadcast networks. For more information, please visit www.oscilloquartz.com.

 

 

Published by
Oscilloquartz
www.oscilloquartz.com

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260601763766/en/

 

Business Wire India

Winston Taylor announces today that Winston & Strawn and Taylor Wessing’s U.K.-led business have officially launched as a single combined firm, creating a premier transatlantic law firm built for the needs of the businesses, people, and markets driving capital and innovation.

 

One of the largest transatlantic firms, with more than 1,400 lawyers spanning the United States, the United Kingdom, Europe, Latin America, and the Middle East, Winston Taylor is built to meet clients’ evolving global needs for counsel.

 

 

“As Winston Taylor, we are centered on a client-first approach and will be working shoulder to shoulder with our clients at the cutting edge of industry and ingenuity,” said Chairman Steve D’Amore. “With that common purpose, we are leveraging both strength and scale by integrating our teams and offices at record speed, working at pace to create a firm that is aligned, focused, and built for the day-to-day needs of our clients as well as their breakthrough moments.”

 

 

Winston Taylor operates out of 20 offices across the major commercial centers that matter to its clients. The firm has strength and depth across its core defining capabilities of major litigation, critical transactions, strategic IP, and private wealth; and is embedded in key client sectors, including technology, media & telecommunications, life sciences & healthcare, financial services, and projects, energy & infrastructure.

 

 

“We have created a unified, transatlantic team focused on providing unparalleled service to clients and attracting the best practitioners in the major hubs of innovation and capital,” said Shane Gleghorn, Managing Partner of Europe and Middle East. “As part of this defining combination, our lawyers have already identified dozens of new cross-border opportunities to serve clients, advising global innovators in key sectors and winning work that is possible because of our newly combined footprint and capabilities.”

 

 

Now complete, Winston Taylor has brought together two firms with more than 400 years of combined history. The firm’s expanded corporate, private equity, real estate, finance, antitrust, regulatory, and private wealth capabilities will provide clients with end-to-end global business strategy and support.

 

 

Notes to Editors

 

 

About Winston Taylor

 

 

Winston Taylor is a transatlantic law firm built for the businesses, people, and markets driving capital and innovation. The firm is present in the major commercial centers that matter to global clients: the U.S., the U.K., Europe, Latin America, and the Middle East. With a team of over 1,400 lawyers, Winston Taylor brings deep experience in Major Litigation, Critical Transactions, Strategic IP, and Private Wealth; and four focus sectors: Technology, Media & Telecommunications, Life Sciences & Healthcare, Financial Services, and Projects, Energy & Infrastructure. Whatever the challenge, Winston Taylor is in the room with its clients, shoulder to shoulder in the everyday moments, and the ones that change everything.

 

 

Please visit winstontaylor.com for additional information about our services, our experience, and the sectors we serve.

 

 

About Winston & Strawn

 

 

Founded in 1853, Winston & Strawn is an Am Law 50 firm with 1,000 lawyers across 14 offices worldwide. The firm is recognized for its leadership in litigation, intellectual property, corporate and finance transactions, and regulatory work across major sectors, including technology, life sciences, and financial services.

 

 

About Taylor Wessing UK

 

 

Founded in 1782, Taylor Wessing UK is a Top 20 UK law firm with over 450 lawyers in the UK, Ireland and the Middle East. The firm is renowned for its Tier 1 intellectual property, life sciences, technology, private wealth, and private equity practices, advising clients ranging from global corporations to leading innovators and investors.

 

 

About Taylor Wessing the Netherlands and Belgium

 

 

Taylor Wessing the Netherlands and Belgium brings together its Amsterdam, Eindhoven, and Brussels offices into a fully integrated Benelux practice, with over 100 lawyers and civil-law notaries advising high-growth technology and life sciences companies, multinational corporates, and investors on corporate transactions, intellectual property, disputes, and regulatory matters.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260601902260/en/

 

Business Wire India

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced the appointment of Kristin Russel as Chief Marketing Officer (CMO). Russel will lead Kinaxis’ global marketing organization, overseeing marketing strategy, corporate and market positioning, digital and brand marketing, communications and go-to-market initiatives.

 

Russel will also take the main stage at Kinexions, where she will discuss practical steps organizations can take to move from decisions to outcomes in an increasingly complex operating environment.

 

 

A tenured marketing executive and recognized industry leader, Russel brings deep experience scaling technology companies and building high impact brands. She joins Kinaxis from symplr, where she served as Chief Marketing Officer and led the development and execution of the company’s comprehensive marketing strategy across branding, digital and product marketing, public relations, community outreach programs, channel partnerships, and business development.

 

 

“Kristin is a proven leader with a track record of building strong brands and connecting strategy to execution,” said Razat Gaurav, Chief Executive Officer of Kinaxis. “As Kinaxis continues to expand its leadership in AI-powered supply chain orchestration and accelerate global growth, Kristin’s experience scaling enterprise technology platforms and transforming go-to-market strategy will help strengthen how we engage customers, partners, and the market.”

 

 

Russel is widely recognized for her leadership in technology and healthcare marketing. She was named one of PR Daily’s 2023 Top Women in Marketing, recognized among Becker’s Top 100 Women in Healthcare, is a two-time 2023 Stevie Award winner, and was recently named to the 2026 B2B CMO 100, recognizing marketing leaders shaping the future of B2B go-to-market strategy.

 

 

“Kinaxis is uniquely positioned at the intersection of AI-powered orchestration, enterprise decision-making and supply chain transformation at a time when organizations are rethinking how they plan and operate in an increasingly complex world,” said Russel. “I’m excited to join the team and help accelerate the company’s next phase of growth as organizations increasingly look to AI-driven technologies to make faster, more confident decisions in the face of constant change.”

 

 

Prior to symplr, Russel led marketing at Quest Analytics and Carrot Inc., driving revenue growth through brand building, demand generation, and strategic partnerships. Earlier in her career, she held senior marketing roles at Humana, Cerner, and Omnicell. She is also a successful entrepreneur, having founded the fintech company Anachron, which was later acquired by ING Bank.

 

 

About Kinaxis

 

 

Kinaxis is a leader in modern supply chain planning and orchestration, powering complex global supply chains, and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

 

 

Source: Kinaxis Inc.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260601953355/en/

 

Business Wire India

Following the introduction of its “Future Landing” vision, GIGABYTE Technology, a global leader in high-performance computing and AI infrastructure, brings that vision to life at COMPUTEX 2026 through a comprehensive showcase of systems, software, and real-world deployments that demonstrate how AI infrastructure is built, deployed, and operated at scale. From rack-scale AI factories and modular data centers to Physical AI workflows, clinical AI applications, and on-prem AI agents, GIGABYTE demonstrates how AI infrastructure moves beyond planning and into production.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525486787/en/

 

 

 

Rack-Scale Infrastructure, Validated for AI Factories

 

At the foundation of “Future Landing” is GIGABYTE’s expanding portfolio of rack-scale AI infrastructure designed for next-generation AI factories.

 

 

Among the latest highlights is the NVIDIA Vera Rubin NVL72, showcased as part of GIGABYTE’s broader rack-scale portfolio. Alongside its rack-scale platforms, GIGABYTE also presents GAIFA (GIGABYTE AI Factory Accelerator), a purpose-built AI factory in Taiwan where next-generation compute, high-speed networking, and NVIDIA’s software stack are integrated into a fully validated environment for system verification, workload optimization, and deployment readiness.

 

 

At the operational layer, GPM (GIGABYTE POD Manager) provides unified visibility and infrastructure-level monitoring across compute, networking, cooling, and power systems, enabling AI factories to operate and scale as a coordinated system.

 

 

Infrastructure Built for Accelerated Deployment

 

 

To accelerate deployment beyond conventional data center construction, GIGABYTE introduces GADU (GIGABYTE Accelerated Deployment Unit), a modular AI infrastructure platform that integrates high-density compute, advanced cooling, and power distribution into transportable, deployment-ready systems. Supporting direct liquid cooling and immersion cooling architectures, GADU enables organizations to expand AI capacity with significantly reduced deployment timelines while maintaining flexibility across diverse operational environments.

 

 

Together with GIGABYTE’s rack-scale systems and infrastructure software, GADU transforms infrastructure into a scalable, rapidly deployable platform.

 

 

Physical AI from Simulation to Action

 

 

Demonstrating how AI moves beyond simulation and into real-world operation, GIGABYTE presents a complete real-to-sim-to-real workflow built on NVIDIA’s full-stack AI platforms.

 

 

The workflow begins with high-fidelity digital twins built through NVIDIA OVX systems, powered by the XLS4-SX2-LAS1 platform on NVIDIA MGX™ architecture with RTX™ PRO GPUs for large-scale Omniverse simulations. AI training then advances through the G2L4-SD4-LA08 platform on NVIDIA HGX™ architecture, where synthetic data generation and reinforcement learning take place. Once validated, trained models are deployed to edge systems powered by NVIDIA Jetson for real-time robotic control, brought to life through live demonstrations alongside Isaac Sim visualizations.

 

 

Clinical AI at the Point of Care

 

 

GIGABYTE also showcases a growing clinical AI ecosystem for real-time medical inference at the point of care. Working alongside healthcare partners, GIGABYTE integrates BRIX mini PCs with AI-assisted diagnostic systems supporting bone marrow smear classification and real-time polyp detection during colonoscopy. The VFG100, an FPGA-accelerated vision platform, delivers real-time image preprocessing with ultra-low CPU overhead, while AI TOP ATOM enables local inference for pulmonary imaging analysis, meeting healthcare data privacy and compliance requirements.

 

 

Bringing AI Closer to Where Decisions Are Made

 

 

Extending AI beyond centralized infrastructure, GIGABYTE also showcases the W775 workstation and AI TOP ATOM desktop AI supercomputer for private training, model customization, and agentic AI workflows powered by NVIDIA NemoClaw.

 

 

Beyond the main showcase on the 1^st floor, visitors can also explore GIGABYTE’s dedicated exhibit on the 4^th floor, where AI TOP systems and consumer AI innovations demonstrate how GIGABYTE’s computing capabilities extend from AI infrastructure to everyday intelligent experiences. At COMPUTEX 2026, GIGABYTE demonstrates how “Future Landing” is turning AI infrastructure into systems that are ready, deployable, and already happening.

 

 

GIGABYTE@COMPUTEX 2026
https://www.gigabyte.com/Events/Computex
June 2-5, 2026
Taipei Nangang Exhibition Center, Hall 1
Enterprise (1F K0802) | Consumer (4F M0520)

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260525486787/en/

 

Business Wire India

BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs.

 

Data from three differentiated BeOne pipeline assets will be presented, including:

 

 

• CDK4 inhibitor (BGB-43395) (poster presentation): First disclosure of anti-tumor activity in first-line (1L) HR+/HER2- metastatic breast cancer.
• B7-H4 ADC (BG‑C9074) (rapid oral presentation): Phase 1 dose-escalation and safety expansion data in advanced solid tumors.
• GPC3x4-1BB (BGB-B2033)bispecific antibody (rapid oral presentation): First clinical data in advanced solid tumors, including hepatocellular carcinoma (HCC), the most common type of liver cancer.

 

Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said: “2026 is an inflection year for BeOne’s solid tumor portfolio, marked by the encouraging data we are presenting at ASCO combined with upcoming readouts at other major congresses. These programs validate our strategy of pairing the right biology with the right modality, and support advancing several assets in different indications into pivotal trials in 2026.”

 

Selective CDK4 inhibitor shows promising efficacy and differentiated safety in first-line breast cancer (Poster Presentation: 180; June 1, 2026, 1:30 PM-4:30 PM CDT)
BeOne will present data about its highly selective CDK4 inhibitor, BGB-43395, in 1L HR+/HER2- metastatic breast cancer, in combination with letrozole, showing promising anti-tumor activity and a favorable safety profile, characterized by infrequent low-grade hematologic toxicities and manageable GI events, which were further mitigated when administered with food. Highlights include:

 

 

• The 240 mg dose of BGB-43395 plus letrozole resulted in a confirmed overall response rate (ORR) of 68.4% (95% CI: 43.4–87.4) and unconfirmed ORR of 73.7% (95% CI: 48.8-90.9).
• The 400 mg dose plus letrozole resulted in a confirmed ORR of 63.2% (95% CI: 38.4–83.7) and unconfirmed ORR of 73.7% (95% CI: 48.8-90.9).
• Low levels of hematologic treatment-related adverse events (TRAEs) with Grade ≥3 neutropenia reported in 5.3% of patients at the 240 mg dose level and 0% at 400 mg, as well as low frequency of fatigue and asthenia; supports profile and validates the molecule’s high selectivity for CDK4.
• GI TRAEs were mitigated when administered with food, all of which were Grade 1.
• Median study follow-up was 12.5 (range, 3.1-15.2) months, 12.4 (range, 8.0-15.0) months, and 10.8 (range, 3.2-12.9) months for the 240 mg, 400 mg, and 600 mg dose groups, respectively.

 

These compelling safety and efficacy findings support the rationale to initiate a global, randomized Phase 3 clinical trial with BGB-43395 in combination with letrozole in 1L HR+/HER2- metastatic breast cancer. The trial, KANDELA-302 (NCT07492641), will begin enrolling patients this month.

 

B7-H4 ADC demonstrates encouraging efficacy supporting advancement in ovarian cancer (Rapid Oral Abstract: 3013; June 2, 2026, 9:45-11:15 AM CDT)
Data at ASCO from BeOne’s B7‑H4-targeting antibody-drug conjugate (ADC), BG‑C9074, include results from Phase 1 dose‑escalation and safety‑expansion cohorts, demonstrating a combination of early efficacy signals and a favorable tolerability profile. Highlights include:

 

 

• At doses under consideration for future development, confirmed ORR of 45.5% and unconfirmed ORR of 54.5% in ovarian cancer (OC), and 40.0% in triple-negative breast cancer, with median study follow-up of 6.6 (range, 0.3-20.8) months.
• Anti-tumor activity demonstrated in OC regardless of B7-H4 expression level.
• Treatment was generally well tolerated with low rates of discontinuation at <5%; 31.5% of patients experienced Grade ≥3 TRAEs, with no Grade ≥3 nausea at 6 mg/kg adjusted ideal body weight (AIBW) and 1.2% at 8 mg/kg AIBW. Grade ≥3 neutropenia rates were 14.8% at 6 mg/kg AIBW and 34.6% at 8 mg/kg AIBW.
• AIBW-based dosing used in the ongoing phase 1 study of BG-C9074 effectively reduced pharmacokinetic variability compared with total body weight dosing, as presented in a separate abstract (Poster 166) at ASCO.

 

These results support continued advancement of the BG‑C9074 development program, with efforts focused on early‑line OC and additional B7‑H4-expressing tumor types.

 

Potential first-in-class GPC3x4-1BB bispecific demonstrates unprecedented anti-tumor activity in heavily pre-treated HCC patients (Rapid Oral Abstract: 3016; June 2, 2026, 9:45-11:15 AM CDT)
The first clinical data (Phase 1a) for BGB-B2033, a GPC3x4-1BB bispecific antibody, will be presented in a rapid oral session highlighting the first-in-class potential of this program in advanced solid tumors, including heavily pre-treated HCC. BGB-B2033 was rationally designed to target GPC3-expressing tumors, a protein commonly expressed in HCC, the sixth most prevalent cancer and third leading cause of cancer death worldwide,¹ with five-year survival rates of only approximately 20%.²

 

 

Highlights include:

 

 

• At doses ≥300 mg, confirmed ORR was 28.9% and unconfirmed ORR was 31.6%, with median study follow-up of 4.8 (range, 0.3-15.5) months.
• Treatment was generally well tolerated across all dose levels (1-1000 mg every three weeks [Q3W], N = 61) with no significant dose-dependent increase in rates of treatment-emergent adverse events (TEAEs):
  • 68.9% (42) of patients experienced TEAEs; of these:
    • 47.5% (29) were treatment related
    • 8.2% (5) of patients experienced Grade ≥3 TRAEs
    • 4.9% (3) were treatment-related serious adverse events
  • TEAE leading to treatment discontinuation occurred in 3.3% (2) of patients
  • Dose limiting toxicity occurred in 1.6% (1) of patients
• TRAEs that occurred in >5% of patients were limited to increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST), both occurring at Grade ≥3 in only 1.6% of patients.

 

BGB-B2033	300 mg Q3W   (N=14)	600 mg Q3W   (N=14)	1000 mg Q3W   (N=10)
Confirmed ORR (complete response + partial response), n (%)	4 (28.6)	5 (35.7)	2 (20.0)
Unconfirmed ORR (complete response + partial response), n (%)	4 (28.6)	5 (35.7)	3 (30.0)*
*An additional PR (week 36) was reported at 1000 mg, with patient still on treatment, pending confirmation in the next tumor assessment

With ORR levels in heavily pretreated patients on par with the current first-line immunotherapy combination standard of care and a differentiated safety profile, BeOne is moving rapidly to advance clinical development of BGB-B2033. The Company has already announced the initiation of a potentially registration-enabling pivotal study in late-line HCC and planned expansion into earlier lines of therapy and additional tumor types, with the ambition to establish a new standard of care in this difficult-to-treat cancer.

 

Investor webcast to highlight solid tumor pipeline data at ASCO

 

 

BeOne will hold an investor webcast at 7:00 p.m. CDT/8:00 p.m. EDT, today, June 1, 2026. The Company’s leadership team, with clinical commentary by expert physicians, will highlight key solid tumor programs being presented at ASCO, share progress in BeOne’s global R&D portfolio, and outline the strategies and capabilities supporting the Company’s continued growth trajectory.

 

 

Webcast access details are available in the Investors section of BeOne’s website at http://ir.beonemedicines.com, https://hkexir.beonemedicines.com, and https://sseir.beonemedicines.com. An archived webcast will be available on the Company’s website.

 

 

About BGB-43395, a CDK4 inhibitor
BGB-43395 is an investigational cyclin-dependent kinase (CDK) 4 inhibitor being studied in a global clinical development program in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The program includes KANDELA-302 (NCT07492641), a randomized Phase 3 clinical trial, initiated in Q2 2026 in first-line metastatic HR+/HER2- breast cancer. BGB-43395 is highly potent and selective CDK4 inhibitor and has the potential to reduce the dose-limiting hematologic toxicities that exist with the current CDK4/6 standard of care and may improve tolerability and enable deeper CDK4 inhibition.

 

 

About BG-C9074, a B7-H4-targeting ADC
BG-C9074, an investigational topoisomerase I inhibitor ADC that targets the B7-H4 protein, which is broadly expressed in breast and gynecologic cancers, is designed with an innovative drug linker to deliver a potent cancer-killing drug directly to the cancer cells. In a Phase 1 study of BG-C9074 (NCT06233942), patients with advanced solid tumors, irrespective of B7-H4 expression, received BG-C9074 every 3 weeks in escalating doses from 1 to 9 mg/kg. A subsequent safety expansion cohort received BG-C9074 in doses ranging from 4 to 8 mg/kg. Endpoints included safety, recommended dose for expansion, preliminary antitumor activity and pharmacokinetic measures.

 

 

About BGB-B2033, a GPC3x4-1BB bispecific antibody
BGB-B2033 is a bispecific antibody targeting GPC3 (glypican 3), a tumor-specific antigen highly expressed in hepatocellular carcinoma (HCC),³ and 4-1BB, a co-stimulatory receptor associated with T-cell activation and tumor reactivity in HCC.⁴ The molecule has been designed with reduced antibody-dependent cellular cytotoxicity (ADCC) to prevent systemic toxicity. BGB-B2033 is being investigated in a Phase 1 study (NCT06427941) in patients with GPC3-expressing advanced solid tumors with at least one prior line of therapy. Patients received BGB-B2033 every 3 weeks in eight escalating dose levels from 1 to 1000 mg, with various safety and anti-tumor activity endpoints. In December 2025, the FDA granted Fast Track Designation to BGB-B2033 for the treatment of HCC, followed by Orphan Drug Designation in March 2026.

 

 

About BeOne
BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

 

 

Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding its solid tumor pipeline; and BeOne’s plans, commitments, aspirations, and goals under the heading “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.

 

 

To access BeOne media resources, please visit ourNewsroomsite.

 

 

1 Samant H, Amiri HS, Zibari GB. Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. J Gastrointest Oncol. 2021 Jul;12(Suppl 2):S361-S373. doi: 10.21037/jgo.2020.02.08. PMID: 34422400; PMCID: PMC8343080.
2 National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Accessed April 2026.
3 Fanching Lin et al. Novel GPC3-targeting radiopharmaceutical therapy for hepatocellular carcinoma. J Clin Oncol 42, 525-525(2024).DOI:10.1200/JCO.2024.42.3_suppl.525
4 Kim DY et al. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. Hepatology, VOL. 71, NO. 3, 2020. https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.30881

 

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260601948824/en/

 

Business Wire India

Omdia’s latest TV & Video market data shows global online video subscriptions reached 2.24 billion at the end of 2025, up 17.6% year on year from 1.9 billion in 2024. However, growth is expected to slow to single digits in 2026 as the market enters a more mature phase. Meanwhile, global pay-TV subscriptions continued their gradual decline, falling 1.8% year on year to 1.03 billion. The balance of the global TV and video market continues to shift toward streaming, with online video accounting for 68.4% of the combined 3.3 billion subscriptions worldwide.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260529336169/en/

 

 

 

In terms of revenue, online video overtook pay-TV for the first time in 2025, Online video revenue increased 13.5% to $176 billion while pay TV revenue declined 4% to $170 billion. Both figures include subscription and transactional revenue but exclude advertising.

 

Omdia’s global data reflects a wide range of different trends taking place at the local level across the markets it tracks. A key common theme, however, is that new, lower cost, ad-supported tiers have been attracting new subscribers into the online video segment.

 

 

Adam Thomas, Practice Leader, Media, Entertainment & Advertising team, said: “The 17.6% increase in subscriptions in 2025 was the largest annual rise since 2021. That growth was driven, in particular, by subsidized ad-tier subscriptions offered by telcos and pay-TV operators. The popularity of these lower-cost offers is a key factor behind the fact that subscription numbers grew by 17.6%, while revenue increased by a more moderate 13.5%.”

 

 

Another clear trend across the sector is that online video platforms are changing their focus from growing subscriber numbers to maximizing revenue from their existing client base, often through price increases for their premium, non-ad-supported tiers. This trend is expected to remain prominent in the years ahead. While the 2025 figures show that discounted ad-tier pricing can attract significant numbers of cost-conscious subscribers into the online video ecosystem, this will be a short-term phenomenon. With several core online video markets approaching saturation Omdia believes the focus on price rises to maximize profits will result in slower subscription, forecasting 5.6% growth for full-year 2026.

 

 

Tony Gunnarsson, Senior Principal Analyst, TV & Online Video added: “It’s clear that the availability of attractively priced ad-tier options created a temporary uplift in SVOD subscriber numbers in 2025. However, this has not changed our longer-term forecast, which remains for low single-digit annual growth rates for the foreseeable future.”

 

 

ABOUT OMDIA

 

 

Omdia, part of TechTarget, Inc. d/b/a Informa TechTarget (Nasdaq: TTGT), is a technology research and advisory group. Our deep knowledge of tech markets grounded in real conversations with industry leaders and hundreds of thousands of data points, make our market intelligence our clients’ strategic advantage. From R&D to ROI, we identify the greatest opportunities and move the industry forward.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260529336169/en/

 

Business Wire India

 

• Procore is the solution to fragmented data, helping ensure information integrity from approved design to handover
• Connects the full project lifecycle in one trusted environment with a single source of truth across BIM, Documents, Quality, and Assets
• Transforms BIM into a live execution workspace via BIM Model Manager, streaming models of any size directly to mobile devices to connect real-time project data with 3D coordination
• Leverages Procore AI with embedded Datagrid capabilities to turn project data into an actionable foundation, powering agentic AI coworkers that can help automate construction workflows and execute work directly within the platform

 

Procore Technologies, Inc. (NYSE: PCOR), the leading global provider of construction management software, today announced the launch of its connected Common Data Environment (CDE)—a purpose-built CDE from the ground up on a single platform to unify and verify project data from approved design to handover, capturing evidence in the flow of work to help keep the digital record aligned with site reality. This trusted data foundation allows agentic AI to act across the full construction lifecycle.

 

In an industry where fragmented information continues to slow decision-making and contribute to costly delays, connected data is increasingly defining top-performing organizations. New research from Dodge Construction Network* found firms with optimized data practices achieve up to 23% higher productivity, manage 27.8% greater construction volume using the same resources, and reduce project delays by more than six days. Those firms also report up to 40% stronger overall performance, highlighting why a trusted data foundation is becoming essential for AI adoption, operational efficiency, and ultimately, better project execution.

 

 

Procore’s connected CDE directly addresses this challenge—transforming document storage into an active governance environment that connects the approved design to site execution across the full project lifecycle—all powered by AI. For European teams operating under ISO 19650 and the Building Safety Act, this connected record helps provide the defensible audit trail required to meet compliance obligations at every stage.

 

 

“While construction has made significant progress in digitizing workflows, many organizations still operate across disconnected systems and siloed project data,” said Lee Miles, General Manager, Europe, Middle East and Africa (EMEA) at Procore. “The challenge is no longer simply moving from paper to digital, but ensuring information flows consistently across teams, processes and the full project lifecycle. As regulatory expectations rise, projects become more complex, and firms adopt AI, connected data is becoming a competitive advantage. Organizations are moving beyond simple document storage and toward trusted and connected information environments that help improve performance today and enable agentic AI to operate with confidence.”

 

 

Creating the Trusted Environment Required for Agentic AI

 

 

Procore’s CDE creates the foundation for AI to move beyond surfacing information and toward executing work.

 

 

The expanded Procore AI experience embeds Datagrid directly into Procore, introducing agentic AI coworkers designed to automate construction workflows and take action within the platform. Built to help eliminate administrative friction rather than replace professional judgment, this approach accelerates execution while project teams retain control, accountability, and final decision-making authority. These AI capabilities can reason across project context, understand relationships between workflows and data, and support execution in complex construction environments.

 

 

“We’re on track to reduce construction administration work with respect to RFI creation, response, and submittal review by 50%,” said Alain Waha, Chief Technology Officer of Buro Happold. “By embedding AI directly into project workflows, teams can spend less time navigating information and more time advancing the work.”

 

 

By connecting AI to structured project datasets—including BIM models, drawings, specifications, RFIs, submittals, and field activity—Procore AI gains a deeper understanding of both spatial and operational context. This enables teams to turn fragmented project information into immediate, actionable insights.

 

 

The Procore AI experience with Datagrid intelligence embedded directly into the platform can surface answers already contained within project records before new RFIs are created, identify discrepancies between approved designs and field execution, and accelerate issue resolution by connecting related workflows, documents, and historical project context. Tasks that previously required hours of manual searching and coordination can be completed in minutes, with transparent source attribution.

 

 

Unlike horizontal AI tools, Procore AI is purpose-built for construction and grounded in verified project data. When teams encounter coordination challenges, project risks, or emerging safety concerns, Procore AI does more than retrieve information—it helps identify root causes earlier, recommend next actions, and reduce the downstream impacts that drive delays, rework, and cost overruns.

 

 

Procore will be showcasing its new CDE and Procore AI offering at Digital Construction Week (stand D200) in London, June 3-4.

 

 

Market Availability

 

 

Developed specifically for European market requirements, Procore’s CDE will initially launch in the UK and Ireland before expanding across EMEA.

 

 

Procore has established a localized UK Data Zone, with a dedicated EU Data Zone planned for launch in fall 2026. The platform supports key industry standards, including ISO 19650 and the Building Safety Act–with Cyber Essentials certification targeted for year end.

 

 

*Dodge-Procore Research Methodology

 

 

The ‘Quantifying The Value Of Construction Management Software’ study was conducted in 2025 to investigate the return on investment that clients and contractors experience from their use of construction management software. An online survey was used to gather the responses of contractors and clients on whether they experienced 62 specific benefits from their use of the software. Nearly half (45%) of the 62 benefits included a follow-up question on quantifiable outcomes or more detailed findings.

 

 

The survey was fielded by Dodge Construction Network. Procore also invited its users to participate. The findings include users of 11 different brands of construction management software. 688 responses were received from construction management software users in the United Kingdom and Ireland.

 

 

About Procore

 

 

Procore Technologies, Inc. (NYSE: PCOR) is a leading technology partner for every stage of construction. Built for the industry, Procore’s unified technology platform drives efficiency and mitigates risk through AI & data-driven insights and decision making. Over three million projects have run on Procore across 150+ countries. For more information, visit https://www.procore.com/.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260601616595/en/

 

Business Wire India

• AIR 377: Jai Somani (Infinity Learn)

• AIR 500: Shashank Maurya (Sri Chaitanya Academy, Varanasi)

• AIR 769: Nishank Vyas (Sri Chaitanya Academy, Bengaluru)

Infinity Learn by Sri Chaitanya, India’s leading hybrid learning platform, today announced its continued streak of success with remarkable student outcomes in the JEE Advanced 2026 examinations. Excelling across both online and offline learning formats, Infinity Learn has once again showcased the strength of its hybrid learning model in JEE Advanced, one of India’s most competitive and sought-after entrance examinations for admission to premier engineering institutions such as the IITs and IIITs.

Among the top achievers, Infinity Learn’s online student Jai Somani secured an impressive All India Rank (AIR) 377. Adding to the institutional glory, Sri Chaitanya Academy Varanasi offline student Shashank Maurya sealed AIR 500, and Sri Chaitanya Academy Bengaluru student Nishank Vyas secured AIR 769. These consistent rankings reflect the strength of a proven ecosystem that combines Sri Chaitanya’s four decades of academic excellence with Infinity Learn’s technology-driven hybrid learning model, seamlessly integrating online and offline learning experiences.

Commenting on the steady growth trajectory, Sushma Boppana, CEO & Director, Sri Chaitanya Educational Institutions & Founder, Infinity Learn, said: “We are immensely proud to see Infinity Learn emerge as a trusted name in education, delivering consistent results and creating meaningful student success stories year after year across both digital and classroom learning environments. The exceptional performance of our learners reflects their deep dedication and the unwavering commitment of our faculty. As a premier educational institution, we remain deeply invested in democratising education, elevating talent to its fullest potential, and strengthening the trust parents place in us. Congratulations to all our students and their families.”

Expanding on this vision of multi-channel educational delivery, Ujjwal Singh, Founding CEO of Infinity Learn by Sri Chaitanya, added: “At Infinity Learn, outcomes define our ultimate purpose. I am incredibly happy that year after year we continue to strengthen our performance across both our online platform and offline centres, enabling students nationwide to secure opportunities at premier engineering institutions and fulfil their aspirations. Our hybrid model enables students in Tier 2 and Tier 3 cities to access the same high-quality, outcome-driven education as those in major metros, proving that excellence is not defined by geography. Our core promise will always remain: Baccha Sekha ki nahi. I extend my heartfelt congratulations to our students and their families for their outstanding success, and to our faculty for their exceptional dedication and commitment to student outcomes.”

As Infinity Learn continues to scale its hybrid infrastructure, these results cement its position as one of India’s most reliable platforms for admission in top-tier engineering institutes across India.